Both in Biotechnology
AIM ImmunoTech vs Intensity Therapeutics
Over the past year AIM returned −91.5% and INTS returned −78.2%; their daily moves had a correlation of -0.10.
AIM −91.5% INTS −78.2%Growth of $1, one year, split-adjusted
| Metric | AIM | INTS |
|---|---|---|
| Price | $0.1521 | $3.10 |
| Market cap | $6.1M | $10.1M |
| Today | −5.53% | −11.43% |
| 1 month | −16.8% | −18.4% |
| 6 months | −72.8% | −39.3% |
| Year to date | −86.5% | −69.8% |
| 1 year | −90.5% | −76.8% |
| Revenue growth (YoY) | +4.0% | — |
| Gross margin | 80.8% | — |
| Net margin | −26876.9% | — |
| P/E (TTM) | — | — |
| Price / sales | 63.9× | — |
| Net cash | $6.3M | $9.5M |
| Dividend yield | — | — |
| Volatility (60d) | 68.6% | 67.0% |
| Short % of float | 3.6% | 2.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).